Bladder Cancer - Results from #320

Healthcare resource utilization and associated costs in patients with metastatic urothelial carcinoma: a real-world analysis using German claims data. April 23, 2024

Predicting non-muscle invasive bladder cancer outcomes using artificial intelligence: a systematic review using APPRAISE-AI. April 22, 2024

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. April 22, 2024

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. April 19, 2024

Clinical variables associated with major adverse cardiac events following radical cystectomy. April 19, 2024

Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer. April 19, 2024

Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. April 18, 2024

Adjuvant intravesical therapy in intermediate-risk non-muscle-invasive bladder cancer. April 18, 2024

Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients. April 17, 2024

Prophylactic Use of Biologic Mesh in Ileal Conduit (PUBMIC): A Randomized Clinical Trial. April 17, 2024

Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg) April 16, 2024

Long-Term Outcomes in Patients with Localized Plasmacytoid Bladder Cancer - Expert Commentary April 16, 2024

C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis. April 16, 2024

Impact of Preoperative Plasma Potassium Levels on Oncological Outcomes, Major Complications, and 30-Day Mortality in Bladder Cancer Patients Undergoing Radical Cystectomy. April 16, 2024

Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). April 16, 2024

A paclitaxel-hyaluronan conjugate (ONCOFID-P-B™) in patients with BCG-unresponsive carcinoma in situ of the bladder: a dynamic assessment of the tumor microenvironment. April 15, 2024

Management of Oligometastatic and Locally Recurrent Urothelial Carcinoma. April 15, 2024

Theories behind Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer and update on current management. April 15, 2024

Advances in preclinical assessment of therapeutic targets for bladder cancer precision medicine. April 12, 2024

Bladder Cancer Survivors Who Do Not Smoke Have Better Longitudinal Health Related Quality of Life Measures: An Assessment of the Comparative Effectiveness of Survivorship Health in Bladder Cancer (CEASE-BC) Study. April 12, 2024

Page 17 of 512